GluGene Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $3.52M

  • Investors
  • 2

GluGene Therapeutics General Information

Description

Developer of gene therapy technologies designed to enhance the performance and versatility of adeno-associated virus vectors. The company engages in the production of assembled, directed evolution, and machine learning-based AAV engineering with adhesive molecule assembly to address the limitations of existing technology, enabling biopharmaceutical researchers to achieve organ-specific delivery, antibody resistance, and expanded therapeutic payloads for advanced genetic medicines.

Contact Information

Website
glugene.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 608, 6F, Building A, Daedeok Biz Center
  • 17, Techno 4-ro
  • Daejeon, Yuseong-gu
  • South Korea
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Drug Discovery
Vertical(s)
Digital Health, HealthTech, Life Sciences
Corporate Office
  • Room 608, 6F, Building A, Daedeok Biz Center
  • 17, Techno 4-ro
  • Daejeon, Yuseong-gu
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GluGene Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 12-May-2025 $3.52M Completed Generating Revenue
1. Seed Round 01-Oct-2021 Completed Generating Revenue
To view GluGene Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

GluGene Therapeutics Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 6

    Pending

  • Expiring in next 12 mo

GluGene Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4807011-A1 Adeno-associated virus vector capable of delivering astrocyte-specific gene Pending 08-Nov-2023
WO-2025100977-A1 Adeno-associated virus vector capable of delivering astrocyte-specific gene Inactive 08-Nov-2023
EP-4600254-A1 Adeno-associated virus vector capable of specific gene delivery to pulmonary bronchi Pending 06-Oct-2022
EP-4600254-A4 Adeno-associated virus vector capable of specific gene delivery to pulmonary bronchi Pending 06-Oct-2022
WO-2024076190-A1 Adeno-associated virus vector capable of specific gene delivery to pulmonary bronchi Inactive 06-Oct-2022 C07K14/005
To view GluGene Therapeutics’s complete patent history, request access »

GluGene Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GluGene Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
LSK Investment Venture Capital Minority
HB Investment Venture Capital Minority
To view GluGene Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

GluGene Therapeutics FAQs

  • When was GluGene Therapeutics founded?

    GluGene Therapeutics was founded in 2021.

  • Where is GluGene Therapeutics headquartered?

    GluGene Therapeutics is headquartered in Daejeon, South Korea.

  • What is the size of GluGene Therapeutics?

    GluGene Therapeutics has 16 total employees.

  • What industry is GluGene Therapeutics in?

    GluGene Therapeutics’s primary industry is Therapeutic Devices.

  • Is GluGene Therapeutics a private or public company?

    GluGene Therapeutics is a Private company.

  • What is GluGene Therapeutics’s current revenue?

    The current revenue for GluGene Therapeutics is .

  • How much funding has GluGene Therapeutics raised over time?

    GluGene Therapeutics has raised $3.52M.

  • Who are GluGene Therapeutics’s investors?

    LSK Investment and HB Investment have invested in GluGene Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process